{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:07:49Z","timestamp":1783904869826,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14551-w","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:54:33Z","timestamp":1778925273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of FF\/UMEC\/VI vs BUD\/GLY\/FOR in Moderate-to-Very Severe COPD"],"prefix":"10.1186","volume":"26","author":[{"given":"Jefferson Antonio","family":"Buend\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Mu\u00f1oz-Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Fernanda Manrique","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Andres","family":"Celis-Preciado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"6","key":"14551_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","volume":"8","author":"GBDCRD Collaborators","year":"2020","unstructured":"Collaborators GBDCRD. Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585\u201396.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"14551_CR2","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","volume":"363","author":"JR Hurst","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128\u201338.","journal-title":"N Engl J Med"},{"issue":"3","key":"14551_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","volume":"155","author":"A Qaseem","year":"2011","unstructured":"Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, van der Criner G, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179\u201391.","journal-title":"Ann Intern Med"},{"issue":"9589","key":"14551_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","volume":"370","author":"JA Wedzicha","year":"2007","unstructured":"Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786\u201396.","journal-title":"Lancet"},{"key":"14551_CR5","unstructured":"Vergara Naranjo CA, Rico Mendoza A, Porras Ram\u00edrez A, Rico Mendoza A. Evoluci\u00f3n de la carga de enfermedad de la Enfermedad Pulmonar Obstructiva Cr\u00f3nica (EPOC) en Colombia: An\u00e1lisis de 2015 a 2022. Bogota2024 [Available from: https:\/\/hdl.handle.net\/20.500.12495\/13982."},{"issue":"2","key":"14551_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1378\/chest.07-1361","volume":"133","author":"A Caballero","year":"2008","unstructured":"Caballero A, Torres-Duque CA, Jaramillo C, Bolivar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343\u20139.","journal-title":"Chest"},{"key":"14551_CR7","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.2147\/COPD.S478349","volume":"19","author":"S Muro","year":"2024","unstructured":"Muro S, Seki M, Hurst JR, Petullo D, Marshall J, Bowen K, et al. Triple Therapy with Budesonide\/Glycopyrronium\/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS. Int J Chron Obstruct Pulmon Dis. 2024;19:2729\u201337.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"18","key":"14551_CR8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med"},{"issue":"2","key":"14551_CR9","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s12325-024-03055-w","volume":"42","author":"C Young","year":"2025","unstructured":"Young C, Lee LY, DiRocco KK, Germain G, Klimek J, Laliberte F, et al. Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data. Adv Ther. 2025;42(2):830\u201348.","journal-title":"Adv Ther"},{"issue":"10","key":"14551_CR10","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/j.1365-3156.2008.02116.x","volume":"13","author":"JJ Miranda","year":"2008","unstructured":"Miranda JJ, Kinra S, Casas JP, Davey Smith G, Ebrahim S. Non-communicable diseases in low- and middle-income countries: context, determinants and health policy. Trop Med Int Health. 2008;13(10):1225\u201334.","journal-title":"Trop Med Int Health"},{"key":"14551_CR11","doi-asserted-by":"publisher","first-page":"1321371","DOI":"10.3389\/fmed.2024.1321371","volume":"11","author":"OM Garcia Morales","year":"2024","unstructured":"Garcia Morales OM, Canas-Arboleda A, Rodriguez Malagon MN, Galindo Pedraza JL, Rodriguez Torres P, Avendano Morales VR, et al. Blood eosinophils levels in a Colombian cohort of biomass-and tobacco-related COPD patients. Front Med (Lausanne). 2024;11:1321371.","journal-title":"Front Med (Lausanne)"},{"key":"14551_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/COPD.S184653","volume":"14","author":"M Bogart","year":"2019","unstructured":"Bogart M, Stanford RH, Laliberte F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343\u201352.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"14551_CR13","doi-asserted-by":"publisher","first-page":"106807","DOI":"10.1016\/j.rmed.2022.106807","volume":"197","author":"D Mannino","year":"2022","unstructured":"Mannino D, Bogart M, Wu B, Germain G, Laliberte F, MacKnight SD, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study. Respir Med. 2022;197:106807.","journal-title":"Respir Med"},{"key":"14551_CR14","unstructured":"Salud IdETe. Manual metodol\u00f3gico para la elaboraci\u00f3n de evaluaciones de efectividad, seguridad y validez diagn\u00f3stica de tecnolog\u00edas en salud. Bogota DC2014 [Available from: https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/INEC\/IETS\/manual-metodologico-elaboracion-de-evaluaciones-de-efectividad.pdf"},{"issue":"9","key":"14551_CR15","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1007\/s12325-025-03295-4","volume":"42","author":"JA Wedzicha","year":"2025","unstructured":"Wedzicha JA, Noorduyn SG, Di Boscio V, Le Rouzic O, Majumdar A, Paczkowski R, et al. Comparative Effectiveness of FF\/UMEC\/VI and BUD\/GLY\/FORM in Patients with COPD Stepping Up From Dual Therapy. Adv Ther. 2025;42(9):4432\u201346.","journal-title":"Adv Ther"},{"issue":"1","key":"14551_CR16","doi-asserted-by":"publisher","first-page":"220260","DOI":"10.1183\/20734735.0260-2022","volume":"19","author":"T Soumagne","year":"2023","unstructured":"Soumagne T, Zysman M, Karadogan D, Lahousse L, Mathioudakis AG. Impact of triple therapy on mortality in COPD. Breathe (Sheff). 2023;19(1):220260.","journal-title":"Breathe (Sheff)"},{"key":"14551_CR17","unstructured":"Departamento, Nacional, DANE) DE. (. Archivo Nacional de Datos 2019 [Available from: https:\/\/sitios.dane.gov.co\/anda-index\/"},{"key":"14551_CR18","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2147\/COPD.S381138","volume":"17","author":"E de Nigris","year":"2022","unstructured":"de Nigris E, Treharne C, Brighton N, Holmgren U, Walker A, Haughney J. Cost-Effectiveness of Triple Therapy with Budesonide\/Glycopyrronium\/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study. Int J Chron Obstruct Pulmon Dis. 2022;17:2987\u20133000.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"14551_CR19","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2147\/COPD.S384591","volume":"17","author":"JA Trigueros","year":"2022","unstructured":"Trigueros JA, Garin N, Baloira A, Aceituno S, Calvo A, Prades M, et al. Cost-Effectiveness Analysis of Triple Therapy with Budesonide\/ Glycopyrronium\/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain. Int J Chron Obstruct Pulmon Dis. 2022;17:2905\u201317.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"14551_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12931-022-02123-5","volume":"23","author":"JR Hurst","year":"2022","unstructured":"Hurst JR, Han MK, Singh B, Sharma S, Kaur G, de Nigris E, et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir Res. 2022;23(1):213.","journal-title":"Respir Res"},{"issue":"4","key":"14551_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1164\/rccm.201710-2029OC","volume":"198","author":"KJ Rothnie","year":"2018","unstructured":"Rothnie KJ, Mullerova H, Smeeth L, Quint JK. Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018;198(4):464\u201371.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"14551_CR22","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1378\/chest.130.4.1117","volume":"130","author":"MP Rutten-van Molken","year":"2006","unstructured":"Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006;130(4):1117\u201328.","journal-title":"Chest"},{"key":"14551_CR23","unstructured":"Brito Ordo\u00f1ez KP, Rodr\u00edguez Torres FP. An\u00e1lisis de costo-efectividad de un programa ambulatorio de rehabilitaci\u00f3n pulmonar despu\u00e9s de las exacerbaciones agudas de la EPOC en Colombia: Universidad de La Sabana."},{"key":"14551_CR24","unstructured":"Estadisticas DAN. \u00cdndice de Precios al Consumidor - IPC 2020 [Available from: https:\/\/www.dane.gov.co\/index.php\/estadisticas-por-tema\/precios-y-costos\/indice-de-precios-al-consumidor-ipc"},{"key":"14551_CR25","unstructured":"Social MdSyP. Termometro de precios de Medicamentos 2024 [Available from: https:\/\/www.minsalud.gov.co\/salud\/MT\/paginas\/termometro-de-precios.aspx"},{"key":"14551_CR26","doi-asserted-by":"crossref","unstructured":"Espinosa O, Rodriguez-Lesmes P, Orozco E, Avila D, Enriquez H, Romano G et al. Estimating Cost-Effectiveness Thresholds Under a Managed Healthcare System: Experiences from Colombia. Health Policy Plan. 2021.","DOI":"10.1093\/heapol\/czab146"},{"issue":"2","key":"14551_CR27","first-page":"2","volume":"31","author":"YAJ Medina","year":"2020","unstructured":"Medina YAJ, Iriarte J, Casta\u00f1eda A, Guerrero Y, Garc\u00eda C, et al. Caracter\u00edsticas cl\u00ednicas, uso de recursos y costos directos de pacientes con EPOC de una instituci\u00f3n de salud de Bogot\u00e1. rev colomb neumol [Internet]. 2020;31(2):2.","journal-title":"rev colomb neumol [Internet]"},{"key":"14551_CR28","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2147\/COPD.S391573","volume":"18","author":"ME Machado-Duque","year":"2023","unstructured":"Machado-Duque ME, Gaviria-Mendoza A, Valladales-Restrepo LF, Gonzalez-Rangel A, Laucho-Contreras ME, Machado-Alba JE. Patterns and Trends in the Use of Medications for COPD Control in a Cohort of 9476 Colombian Patients, 2017\u20132019. Int J Chron Obstruct Pulmon Dis. 2023;18:1601\u201310.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"14551_CR29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2147\/COPD.S240556","volume":"15","author":"M Schroeder","year":"2020","unstructured":"Schroeder M, Benjamin N, Atienza L, Biswas C, Martin A, Whalen JD, et al. Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621\u201332.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"14551_CR30","doi-asserted-by":"publisher","first-page":"108254","DOI":"10.1016\/j.rmed.2025.108254","volume":"247","author":"JA Buendia","year":"2025","unstructured":"Buendia JA, Manrique Acevedo LF, Celis Preciado C. Beyond triple Therapy: Is dupilumab a cost-effective option for COPD with type 2 inflammation? Respir Med. 2025;247:108254.","journal-title":"Respir Med"},{"key":"14551_CR31","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.2147\/COPD.S475748","volume":"20","author":"R Cai","year":"2025","unstructured":"Cai R, Martin AA, Ge Y, Risebrough NA, Haeussler K, Compton C, et al. Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK. Int J Chron Obstruct Pulmon Dis. 2025;20:2727\u201343.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"14551_CR32","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.2147\/COPD.S492524","volume":"20","author":"KM Beeh","year":"2025","unstructured":"Beeh KM, Claussen J, Shah D, Martin A, Kendall R, Dasari P, et al. Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective. Int J Chron Obstruct Pulmon Dis. 2025;20:2011\u201322.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"14551_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2147\/COPD.S499686","volume":"20","author":"H Lim","year":"2025","unstructured":"Lim H, Kim DH, Hong SH, Shin J, Lee H, Shin K, et al. Real-World Effectiveness of Single-Inhaler Triple Treatment Through Assorted Respiratory Outcomes When Switched From Multiple-Inhaler Triple Therapies (RESTART): A Prospective Cohort Study of Korean Patients With COPD. Int J Chron Obstruct Pulmon Dis. 2025;20:1039\u201350.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"14551_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/COPD.S427770","volume":"19","author":"KM Beeh","year":"2024","unstructured":"Beeh KM, Scheithe K, Schmutzler H, Kruger S. Real-World Effectiveness of Fluticasone Furoate\/Umeclidinium\/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial. Int J Chron Obstruct Pulmon Dis. 2024;19:205\u201316.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"14551_CR35","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s12325-024-03088-1","volume":"42","author":"D Mannino","year":"2025","unstructured":"Mannino D, Weng S, Germain G, Boudreau J, Tardif-Samson A, Forero-Schwanhaeuser S, et al. Comparative Effectiveness of Fluticasone Furoate\/Umeclidinium\/Vilanterol and Budesonide\/Glycopyrrolate\/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease. Adv Ther. 2025;42(2):1131\u201346.","journal-title":"Adv Ther"},{"key":"14551_CR36","doi-asserted-by":"publisher","first-page":"e080409","DOI":"10.1136\/bmj-2024-080409","volume":"387","author":"WB Feldman","year":"2024","unstructured":"Feldman WB, Suissa S, Kesselheim AS, Avorn J, Russo M, Schneeweiss S, et al. Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study. BMJ. 2024;387:e080409.","journal-title":"BMJ"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14551-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:23:13Z","timestamp":1783902193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14551-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14551"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14551-w","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve direct interaction with human participants or the use of individualized human data. All model parameters were derived exclusively from previously published clinical trials and aggregated secondary data. This study was approved by the Institutional Review Board of University of Antioquia. The need for consent was waived by an IRB (2015\u20134690), following local regulations of resolution 8430\/93, because this is a study which all information was extracted from the literature and does not use data from patients\u201d. Nevertheless, the research was conducted in full accordance with the principles outlined in the Declaration of Helsinki, and no identifiable personal information was collected, accessed, or processed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"962"}}